A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
Publication
, Journal Article
Cloughesy, TF; Prados, MD; Wen, PY; Mikkelsen, T; Abrey, LE; Schiff, D; Yung, WK; Maoxia, Z; Dimery, I; Friedman, HS
Published in: Journal of Clinical Oncology
May 20, 2008
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
2010b / 2010b
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Cloughesy, T. F., Prados, M. D., Wen, P. Y., Mikkelsen, T., Abrey, L. E., Schiff, D., … Friedman, H. S. (2008). A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). Journal of Clinical Oncology, 26(15_suppl), 2010b-2010b. https://doi.org/10.1200/jco.2008.26.15_suppl.2010b
Cloughesy, T. F., M. D. Prados, P. Y. Wen, T. Mikkelsen, L. E. Abrey, D. Schiff, W. K. Yung, Z. Maoxia, I. Dimery, and H. S. Friedman. “A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2010b-2010b. https://doi.org/10.1200/jco.2008.26.15_suppl.2010b.
Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2010b-2010b.
Cloughesy, T. F., et al. “A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2010b-2010b. Crossref, doi:10.1200/jco.2008.26.15_suppl.2010b.
Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2010b-2010b.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
2010b / 2010b
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences